Fast and Secure Delivery Worldwide Express & Expedited Shipping Service
USD $1195.56
Generic Name: Ruxolitinib
IndiaJAKAVI (Ruxolitinib) is a prescription medication used to treat certain conditions related to the immune system, specifically for patients with myelofibrosis and polycythemia vera. It works by inhibiting specific enzymes that play a crucial role in the signaling pathways of the immune system, helping to reduce symptoms and improve quality of life.
JAKAVI is indicated for the treatment of:
Ruxolitinib is a Janus kinase (JAK) inhibitor that selectively inhibits JAK1 and JAK2 enzymes, which are involved in the signaling of various hematopoietic and immune system processes. By blocking these enzymes, JAKAVI helps to decrease inflammation and reduce the overproduction of blood cells.
The recommended dosage of JAKAVI may vary based on the specific condition being treated and the patient's individual response. It is crucial to follow the prescribing physician's instructions regarding dosage and administration.
Like all medications, JAKAVI may cause side effects. Common side effects include:
Patients should report any severe or persistent side effects to their healthcare provider.
Before starting treatment with JAKAVI, inform your healthcare provider about any existing medical conditions, particularly:
Regular monitoring may be required during treatment.
It is essential to consult your healthcare provider for personalized medical advice and to discuss any potential interactions with other medications you may be taking.
